Examining the Metastatic Niche: Targeting the Microenvironment (Q34152023)

31 July 2017

title

Examining the metastatic niche: targeting the microenvironment (English)

1 reference

31 July 2017

Examining the Metastatic Niche: Targeting the Microenvironment (English)

1 reference

Crossref

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

3 September 2024

Theresa Guise

1 reference

31 July 2017

Theresa Guise

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21111245

3 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21111245

3 September 2024

publication date

1 October 2010

1 reference

full work available at URL

31 July 2017

https://api.elsevier.com/content/article/PII:S0093775410001776?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

https://api.elsevier.com/content/article/PII:S0093775410001776?httpAccept=text/plain

3 September 2024

1 reference

Crossref

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

3 September 2024

1 reference

31 July 2017

volume

37 Suppl 2

1 reference

31 July 2017

page(s)

S2-14

1 reference

The bone microenvironment in metastasis; what is special about bone?

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Mechanisms of bone metastasis

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Eating bone or adding it: the Wnt pathway decides

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Regulation of osteoblastogenesis and bone mass by Wnt10b

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Sequential roles of Hedgehog and Wnt signaling in osteoblast development

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Is Wnt signalling the final common pathway leading to bone formation?

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

RANK is essential for osteoclast and lymph node development

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: A structure-function analysis

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Metastasis to bone: causes, consequences and therapeutic opportunities

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Molecular mechanisms and treatment of bone metastasis

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

The metastatic niche: adapting the foreign soil

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Crosstalk between cancer cells and bone microenvironment in bone metastasis

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Mechanisms of cancer metastasis to the bone

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Mechanisms of osteolytic bone metastases in breast carcinoma

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

The IGF system and breast cancer

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

The role of Dickkopf-1 in bone development, homeostasis, and disease

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Increased Dickkopf-1 expression in breast cancer bone metastases

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Prostate cancer cells promote osteoblastic bone metastases through Wnts

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Mitogenic Response of Osteoblast Cells to Prostate-Specific Antigen Suggests an Activation of Latent TGF-β and a Proteolytic Modulation of Cell Adhesion Receptors

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Review of 1027 patients with newly diagnosed multiple myeloma

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Pathogenesis of myeloma bone disease

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Therapeutic implications of osteoprotegerin

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Functional osteoclast-like transformation of cultured human myeloma cell lines.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Pathogenesis of myeloma bone disease.

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Emerging therapeutic targets in breast cancer bone metastasis

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

3 September 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.10.007

3 September 2024

Identifiers

1 reference

31 July 2017

1 reference